Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Smoking associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy

A history of smoking is associated with an increased risk of metastatic disease in patients treated with radiotherapy (XRT) for prostate cancer (CaP), according to a report in the online version of the BJU International.

20 Apr 2007

Steven Piantadosi named as first Director of Samuel Oschin Comprehensive Cancer Institute

Internationally renowned cancer researcher Steven Piantadosi, M.D., Ph.D, has been named director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

20 Apr 2007

Study evaluates CaP risk among finasteride users

Current medical management for BPH includes alpha-blockers and 5- reductase inhibitors.

20 Apr 2007

Prostate cancer treatment decisions can be complicated

For many men with early-stage prostate cancer, sorting out the treatment options can be overwhelming.

20 Apr 2007

Long-term survival probability in men with clinically localized prostate cancer

Randomized studies comparing conservative therapy to definitive therapy in men with prostate cancer (CaP) are underway, but not yet available.

20 Apr 2007

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.

18 Apr 2007

Chemicals in cruciferous vegetables may provide cancer-fighting benefit

Chemicals in cruciferous vegetables, such as broccoli, watercress, cabbage and cauliflower, appear to not only stop human prostate cancer cells from growing in mice but also may cut off the formation of blood vessels that "feed" tumors, says a University of Pittsburgh Cancer Institute study.

18 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Clioquinol shows promise in fighting cancer

Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

18 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Side-effects of treatment for localized prostate cancer

It seems plausible that prostate cancer (CaP) patients might value health states associated with side-effects of treatment for localized CaP as less detrimental than men with no CaP.

17 Apr 2007

Lilly and AACR tackle cancer together

Innovative and collaborative cancer research can be the catalyst to improving patient outcomes.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

Snake venom toxin as a treatment for prostate cancer

This certainly sounds unusual, but Dr. Son and colleagues report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen-independent prostate cancer (AICAP) in the February 2007 issue of Molecular Cancer Therapeutics .

16 Apr 2007